IL202840A - Preserved pyridinone n-aryl, pharmaceuticals including them and their use in the manufacture of drugs to treat fibrosis-mediated disorders and collagen-mediated disorders - Google Patents
Preserved pyridinone n-aryl, pharmaceuticals including them and their use in the manufacture of drugs to treat fibrosis-mediated disorders and collagen-mediated disordersInfo
- Publication number
- IL202840A IL202840A IL202840A IL20284009A IL202840A IL 202840 A IL202840 A IL 202840A IL 202840 A IL202840 A IL 202840A IL 20284009 A IL20284009 A IL 20284009A IL 202840 A IL202840 A IL 202840A
- Authority
- IL
- Israel
- Prior art keywords
- mediated disorders
- fibrotic
- medicaments
- collagen
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94513607P | 2007-06-20 | 2007-06-20 | |
| PCT/US2008/067732 WO2008157786A1 (en) | 2007-06-20 | 2008-06-20 | Substituted n-aryl pyridinones as fibrotic inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL202840A0 IL202840A0 (en) | 2010-06-30 |
| IL202840A true IL202840A (en) | 2014-07-31 |
Family
ID=39731521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL202840A IL202840A (en) | 2007-06-20 | 2009-12-20 | Preserved pyridinone n-aryl, pharmaceuticals including them and their use in the manufacture of drugs to treat fibrosis-mediated disorders and collagen-mediated disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US8383823B2 (OSRAM) |
| EP (1) | EP2170828B1 (OSRAM) |
| JP (1) | JP5587184B2 (OSRAM) |
| KR (2) | KR101583737B1 (OSRAM) |
| CN (2) | CN104892498A (OSRAM) |
| AU (1) | AU2008265595B2 (OSRAM) |
| CA (1) | CA2691379C (OSRAM) |
| DK (1) | DK2170828T3 (OSRAM) |
| ES (1) | ES2400026T3 (OSRAM) |
| HK (1) | HK1214251A1 (OSRAM) |
| IL (1) | IL202840A (OSRAM) |
| NZ (1) | NZ599643A (OSRAM) |
| WO (1) | WO2008157786A1 (OSRAM) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
| CN104892498A (zh) * | 2007-06-20 | 2015-09-09 | 奥斯拜客斯制药有限公司 | 作为纤维化抑制剂的取代的n-芳基吡啶酮 |
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| US20090131485A1 (en) * | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| WO2010065755A1 (en) * | 2008-12-04 | 2010-06-10 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
| AU2010248758A1 (en) * | 2009-05-15 | 2011-11-24 | Intermune, Inc. | Methods of treating HIV patients with anti-fibrotics |
| TWI434833B (zh) | 2009-06-03 | 2014-04-21 | Intermune Inc | 用於合成吡非尼酮（ｐｉｒｆｅｎｉｄｏｎｅ）的改良方法 |
| US20110053968A1 (en) * | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| CN101921225B (zh) * | 2009-06-11 | 2013-04-03 | 北京凯得尔森生物技术有限公司 | 吡啡尼酮类化合物、其制备方法和应用 |
| EP2483406A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| US10092552B2 (en) * | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| CN103561741A (zh) * | 2011-03-08 | 2014-02-05 | 奥斯拜客斯制药有限公司 | 取代的n-芳基吡啶酮 |
| CA2835438A1 (en) * | 2011-05-25 | 2012-11-29 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| PT2753632T (pt) | 2011-09-08 | 2023-08-17 | Sage Therapeutics Inc | Esteróides neuroactivos, composições e respectivas utilizações |
| HK1201298A1 (en) | 2011-11-22 | 2015-08-28 | Intermune, Inc. | Methods of diagnosing and treating idiopathic pulmonary fibrosis |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| US12226407B2 (en) | 2012-07-24 | 2025-02-18 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| WO2014026959A1 (en) * | 2012-08-13 | 2014-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of cystic fibrosis |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| SMT202500336T1 (it) | 2013-03-13 | 2025-11-10 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| CN112057457A (zh) * | 2013-03-13 | 2020-12-11 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| EP3091976B1 (en) | 2014-01-10 | 2024-07-24 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| JP2017503839A (ja) * | 2014-01-24 | 2017-02-02 | オースペックス ファーマシューティカルズ インコーポレイテッド | 置換ｎ−アリールピリジノン |
| KR20160117596A (ko) | 2014-02-07 | 2016-10-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 신규 제약 제제 |
| WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| US20150284327A1 (en) * | 2014-04-04 | 2015-10-08 | Auspex Pharmaceuticals, Inc. | Oxindole inhibitors of tyrosine kinase |
| WO2015171345A1 (en) * | 2014-04-30 | 2015-11-12 | Auspex Pharmaceuticals, Inc. | N-aryl pyridinones modulators of fibrosis and/or collagen infiltration |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PT3256138T (pt) * | 2015-02-10 | 2022-05-23 | Axsome Therapeutics Inc | Composições farmacêuticas compreendendo meloxicam |
| JP6882996B2 (ja) | 2015-07-06 | 2021-06-02 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびそれらの使用の方法 |
| CN113292623A (zh) | 2015-07-06 | 2021-08-24 | 萨奇治疗股份有限公司 | 孕甾醇及其使用方法 |
| AU2016289971C1 (en) | 2015-07-06 | 2022-12-08 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN105315198A (zh) * | 2015-11-02 | 2016-02-10 | 重庆康乐制药有限公司 | 一种吡非尼酮的晶型及其制备方法 |
| CN105330598B (zh) * | 2015-12-02 | 2017-11-14 | 新发药业有限公司 | 一种吡非尼酮的制备方法 |
| WO2017165497A1 (en) * | 2016-03-22 | 2017-09-28 | Leof Edward B | Using fatty acid synthase inhibitors to treat fibrosis |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| JP7112331B2 (ja) | 2016-04-01 | 2022-08-03 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| PL3439655T3 (pl) | 2016-04-08 | 2021-09-27 | Quretech Bio Ab | Tiazolino 2-pirydony o skondensowanych pierścieniach, sposoby ich wytwarzania oraz ich zastosowanie do leczenia i/lub profilaktyki gruźlicy |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| TWI752976B (zh) | 2016-07-07 | 2022-01-21 | 美商賽吉醫療公司 | 氧固醇(oxysterol)及其使用方法 |
| CA3038900A1 (en) | 2016-09-30 | 2018-04-05 | Sage Therapeutics, Inc. | C7 substituted oxysterols and methods as nmda modulators |
| CN115322238A (zh) | 2016-10-18 | 2022-11-11 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CN115181153A (zh) | 2016-10-18 | 2022-10-14 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| CN106748984A (zh) * | 2016-11-22 | 2017-05-31 | 斯芬克司药物研发（天津）股份有限公司 | 6‑羟甲基‑1‑苯基吡啶‑2‑酮及其制备方法与应用 |
| CA3108048A1 (en) * | 2017-07-31 | 2019-02-07 | Washington University | Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| CN108285431B (zh) * | 2018-03-23 | 2021-04-09 | 北京康蒂尼药业股份有限公司 | 一种吡非尼酮有关物质及其制备方法和用途 |
| WO2022010925A1 (en) * | 2020-07-06 | 2022-01-13 | Puretech Lyt 100, Inc. | Methods of treating diseases and disorders with deupirfenidone |
| US20250114341A1 (en) * | 2018-09-14 | 2025-04-10 | Puretech Lyt 100, Inc. | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone |
| KR20210076000A (ko) * | 2018-09-14 | 2021-06-23 | 퓨어테크 엘와이티 100, 아이엔씨. | 중수소 농축 피르페니돈 및 이의 사용 방법 |
| EP4121049A4 (en) * | 2020-03-18 | 2024-04-03 | Puretech Lyt 100, Inc. | Methods of treating lymphedema with deupirfenidone |
| CN114957106B (zh) * | 2022-05-23 | 2024-01-30 | 湖北工程学院 | 药物吡非尼酮的流动相自动合成方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02215719A (ja) | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ATE372966T1 (de) | 1994-03-25 | 2007-09-15 | Isotechnika Inc | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| US5962478A (en) | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| PT1104760E (pt) | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| EP1134290A3 (en) | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| WO2001092188A1 (en) | 2000-05-29 | 2001-12-06 | Shionogi & Co., Ltd. | Method for labeling with tritium |
| US20060270618A1 (en) * | 2001-12-18 | 2006-11-30 | Dorian Bevec | Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases |
| JP4164031B2 (ja) | 2002-02-14 | 2008-10-08 | ファルマシア コーポレーション | Ｐ３８ｍａｐキナーゼのモジュレータとしての置換されたピリジノン |
| CA2496577A1 (en) | 2002-08-28 | 2004-03-11 | Intermune, Inc. | Combination therapy for treatment of fibrotic disorders |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US20070072181A1 (en) | 2003-02-28 | 2007-03-29 | Blatt Lawrence M | Combination therapy for treating alphavirus infection and liver fibrosis |
| WO2004105684A2 (en) | 2003-05-16 | 2004-12-09 | Intermune, Inc. | Combination therapy for proliferative disorders |
| WO2005038056A1 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Combination therapy for the treatment of viral diseases |
| WO2005040758A2 (en) | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| JP4072623B2 (ja) | 2004-03-09 | 2008-04-09 | 独立行政法人産業技術総合研究所 | ピリジン−ｎ−オキシド類の製造方法 |
| WO2005110478A2 (en) | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
| PT1928454E (pt) | 2005-05-10 | 2014-12-04 | Intermune Inc | Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress |
| US20080033011A1 (en) | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| MX2009002398A (es) | 2006-09-05 | 2009-03-16 | Schering Corp | Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica. |
| US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| CN104892498A (zh) * | 2007-06-20 | 2015-09-09 | 奥斯拜客斯制药有限公司 | 作为纤维化抑制剂的取代的n-芳基吡啶酮 |
| US20090131485A1 (en) | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| WO2010065755A1 (en) | 2008-12-04 | 2010-06-10 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
| SG172981A1 (en) | 2009-01-26 | 2011-08-29 | Intermune Inc | Methods for treating acute myocardial infarctions and associated disorders |
| CN102149682B (zh) | 2009-05-25 | 2012-12-05 | 中南大学 | 1-(取代芳基)-5-三氟甲基-2-（1h）吡啶酮化合物及其盐的制备方法及其用途 |
| CN103561741A (zh) | 2011-03-08 | 2014-02-05 | 奥斯拜客斯制药有限公司 | 取代的n-芳基吡啶酮 |
| CA2835438A1 (en) | 2011-05-25 | 2012-11-29 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
| JP2017503839A (ja) | 2014-01-24 | 2017-02-02 | オースペックス ファーマシューティカルズ インコーポレイテッド | 置換ｎ−アリールピリジノン |
| WO2015171345A1 (en) | 2014-04-30 | 2015-11-12 | Auspex Pharmaceuticals, Inc. | N-aryl pyridinones modulators of fibrosis and/or collagen infiltration |
-
2008
- 2008-06-20 CN CN201510221701.2A patent/CN104892498A/zh active Pending
- 2008-06-20 CA CA2691379A patent/CA2691379C/en active Active
- 2008-06-20 CN CN200880102512A patent/CN101842355A/zh active Pending
- 2008-06-20 AU AU2008265595A patent/AU2008265595B2/en active Active
- 2008-06-20 EP EP08771632A patent/EP2170828B1/en active Active
- 2008-06-20 KR KR1020107001341A patent/KR101583737B1/ko active Active
- 2008-06-20 US US12/143,484 patent/US8383823B2/en active Active
- 2008-06-20 DK DK08771632.0T patent/DK2170828T3/da active
- 2008-06-20 WO PCT/US2008/067732 patent/WO2008157786A1/en not_active Ceased
- 2008-06-20 KR KR1020167000072A patent/KR101767849B1/ko active Active
- 2008-06-20 ES ES08771632T patent/ES2400026T3/es active Active
- 2008-06-20 JP JP2010513457A patent/JP5587184B2/ja active Active
- 2008-06-20 NZ NZ599643A patent/NZ599643A/xx unknown
-
2009
- 2009-12-20 IL IL202840A patent/IL202840A/en active IP Right Grant
-
2012
- 2012-10-29 US US13/663,188 patent/US8680123B1/en active Active
-
2013
- 2013-12-18 US US14/132,528 patent/US8969575B2/en active Active
-
2014
- 2014-04-30 US US14/266,048 patent/US9062001B2/en active Active
- 2014-08-08 US US14/455,339 patent/US8969576B2/en active Active
-
2015
- 2015-05-21 US US14/718,993 patent/US9504677B2/en active Active
-
2016
- 2016-02-24 HK HK16102071.0A patent/HK1214251A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160007684A (ko) | 2016-01-20 |
| CN104892498A (zh) | 2015-09-09 |
| WO2008157786A1 (en) | 2008-12-24 |
| US8680123B1 (en) | 2014-03-25 |
| US8969575B2 (en) | 2015-03-03 |
| CN101842355A (zh) | 2010-09-22 |
| KR20100050466A (ko) | 2010-05-13 |
| US20140235677A1 (en) | 2014-08-21 |
| US9062001B2 (en) | 2015-06-23 |
| KR101767849B1 (ko) | 2017-08-11 |
| AU2008265595A1 (en) | 2008-12-24 |
| DK2170828T3 (da) | 2013-03-04 |
| US20140348928A1 (en) | 2014-11-27 |
| US20140107040A1 (en) | 2014-04-17 |
| EP2170828B1 (en) | 2012-11-21 |
| CA2691379C (en) | 2015-06-09 |
| HK1214251A1 (zh) | 2016-07-22 |
| US8383823B2 (en) | 2013-02-26 |
| KR101583737B1 (ko) | 2016-01-11 |
| US20080319026A1 (en) | 2008-12-25 |
| NZ599643A (en) | 2013-11-29 |
| EP2170828A1 (en) | 2010-04-07 |
| IL202840A0 (en) | 2010-06-30 |
| ES2400026T3 (es) | 2013-04-05 |
| CA2691379A1 (en) | 2008-12-24 |
| US8969576B2 (en) | 2015-03-03 |
| AU2008265595B2 (en) | 2014-12-04 |
| US20150250777A1 (en) | 2015-09-10 |
| JP5587184B2 (ja) | 2014-09-10 |
| US9504677B2 (en) | 2016-11-29 |
| JP2010530897A (ja) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL202840A (en) | Preserved pyridinone n-aryl, pharmaceuticals including them and their use in the manufacture of drugs to treat fibrosis-mediated disorders and collagen-mediated disorders | |
| IL274602B (en) | Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and their use in the preparation of drugs for the treatment of thrombocytopenia | |
| IL189578A (en) | Pyridine derivatives, pharmaceutical compounds containing them, and their use in the preparation of drugs for the treatment of cns diseases | |
| IL200924A (en) | Amino pyridine, pharmaceuticals including anthem and their use in the manufacture of drugs for the treatment of cell proliferation | |
| IL206296A (en) | History of aminopyrazole, and their medicinal products and their use in the preparation of drugs for the prevention and treatment of diseases | |
| IL205624A (en) | Carboxamide, Sulfonamide and Amine Compounds, Their Pharmaceutical Preparations | |
| IL202158A (en) | History of Oxadiazole, Pharmaceuticals Containing Them and Their Use in the manufacture of Drugs for the Treatment of Neurological and Psychiatric Disorders | |
| IL217378A (en) | History of oxazin, containing pharmaceuticals and their use in the preparation of drugs for the treatment of neurological disorders | |
| IL204887A (en) | Acetamide History, Pharmaceuticals Containing Them, Methods of Preparing and Using It in the Preparation of Diabetes Medications | |
| IL210452A (en) | Annotations of dimethyl-oxo-dihydro- (pyridine-3-or-4-ram) -phenyl-6-methyl-6-phenyl- [1,3] -oxiazine-2-one | |
| IL217490A (en) | History of pyridine-4-il, pharmaceutical preparations containing them and their use in the preparation of medicines | |
| IL209121A (en) | Indazolil history, their medicinal preparations and their use in the preparation of medications for the treatment of inflammatory diseases | |
| IL193678A (en) | Derivatives of pyrazolyl-theophane, pharmaceuticals containing them and their use in the preparation of drugs to improve cognitive activity | |
| IL206952A (en) | History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines | |
| IL193762A (en) | The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs | |
| TWI369987B (en) | New pharmaceutical compositions for the treatment of hyper-proliferative disorders | |
| IL199187A (en) | Indole history, pharmaceuticals including them and their use in the manufacture of medicines | |
| IL219437A (en) | Converted benzamide histories, processes for their preparation, pharmacological compounds containing them and their use in the preparation of drugs for the treatment of cardiovascular diseases | |
| IL191310A (en) | A variant of the factor xa enhancer hemostasis, a pharmaceutical product containing it, and its use in the preparation of drugs for the treatment of hemostasis-related diseases | |
| EP1986639A4 (en) | PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES | |
| IL202515A (en) | Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases | |
| IL203936A (en) | HISTORY 4 - Pyrimidinsulfamide, Process for Preparation, Pharmaceutical Preparations Containing and Using it for Medication Preparation | |
| IL181734A (en) | Surapnib Tosylate Polymorph, Pharmaceuticals Containing It and Using It to Make Medicines | |
| IL197128A (en) | History of pyridone, pharmaceutical preparations containing them and their use in the preparation of drugs that affect eating behavior. | |
| IL199152A (en) | Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |